Lexaria Bioscience reports Form D covering warrant exercise proceeds

Lexaria Bioscience Corp., based in Kelowna, British Columbia, filed a Form D notice with the SEC on September 18, 2026, reporting a first sale date of September 9, 2026. The filing was a new notice, not an amendment.¹

The offering involved rights to acquire securities rather than equity or debt directly. The security type checked was an option, warrant or other right to acquire another security.¹ The filing states the reported figures reflect proceeds tied to warrant exercises. The filing lists total offering and total amount sold at $113,492, with the clarification that this value represents proceeds received from warrants issued under an arrangement in which holders agreed to exercise at market price in exchange for replenishment warrants set at double the amount exercised.¹

Three investors had already put money into the offering as of the filing date.¹ Lexaria's issuer size was listed in the $5,000,001 to $25,000,000 range.¹

On compensation, H.C. Wainwright & Co. is named as a sales compensation recipient tied to the transaction. Sales commissions were listed at $7,944, described as 7% of monies received for the warrants issued, with the placement agent also receiving a further payment equal to 7% of proceeds generated when warrants were exercised under the inducement agreement, amounting to roughly $402,625.¹

No proceeds from the offering were designated for payments to executive officers, directors, or promoters.¹ The company stated the offering was not made in connection with a business combination transaction such as a merger or acquisition.¹ The notice was signed by Richard Christopher, listed as CEO, on September 18, 2026.¹